Silybin

Silybin at a Glance

Silybin — known pharmaceutically as silibinin — is the principal flavonolignan of the silymarin complex extracted from milk thistle (Silybum marianum) seed. It makes up roughly 40–60% of that complex and is by far its most-studied component, so most of what people mean by “milk thistle’s liver activity” is, at the molecular level, largely a silybin story ^{1,3Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 3Gazák R et al. · 2007Silybin and silymarin—new and emerging applications in medicineView study →}. It is not a single compound but an almost 1:1 mixture of two diastereomers, silybin A and silybin B, which differ subtly in potency ^{3Reference 3Gazák R et al. · 2007Silybin and silymarin—new and emerging applications in medicineView study →}.

The evidence has one genuine, hard-to-beat human anchor: intravenous silibinin (Legalon SIL) is an established clinical antidote for Amanita phalloides (“death cap”) mushroom poisoning ^{8Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →}. Beyond that, silybin is researched for chronic liver disease, liver fibrosis, hepatitis C, prostate cancer chemoprevention and metabolic endpoints — but almost all oral human trials test the silymarin complex, not purified silybin, and its poor oral bioavailability is the recurring limitation that phospholipid formulations (Siliphos) and the intravenous route exist to solve ^{1,16Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}. Toxicity is low.

Established Uses: The Amanita Antidote

The one place silybin functions as a drug rather than a supplement constituent is emergency medicine. In poisoning by amatoxin-containing mushrooms (chiefly Amanita phalloides), the toxin α-amanitin is carried into liver cells by the sinusoidal uptake transporters OATP1B3 and NTCP; once inside, it inhibits RNA polymerase II and kills hepatocytes, causing fulminant liver failure ^{9Reference 9Letschert K et al. · 2006Molecular characterization and inhibition of amanitin uptake into human hepatocytesView study →}. Intravenous silibinin (silibinin dihydrogen disuccinate, Legalon SIL) competitively blocks that hepatocyte uptake, interrupts enterohepatic recirculation of the toxin, and buys time for the liver to recover ^{8,9Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →Reference 9Letschert K et al. · 2006Molecular characterization and inhibition of amanitin uptake into human hepatocytesView study →}.

This is a real, human, life-threatening indication with a decades-long observational track record and an FDA orphan-drug pathway — not an in-vitro extrapolation. It is the strongest single justification for taking silybin’s pharmacology seriously, even though it uses the intravenous route precisely because oral silybin cannot reach the needed hepatic concentrations ^{8Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →}.

Silybin, Silibinin & the Silymarin Complex

The naming around this molecule causes real confusion, so it is worth stating plainly:

• Silymarin is the complex — the whole flavonolignan mixture from milk thistle seed (silybin, isosilybin, silychristin, silydianin and minor congeners). It is a fraction, not a molecule, and it is the entity actually tested in most trials ^{2,14Reference 2Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →Reference 14Zhong S et al. · 2017Meta-analysisThe therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trialsView study →}.
• Silybin is the single dominant molecule within that complex (~40–60%).
• Silibinin is the INN / pharmaceutical name for the same molecule — “silybin” and “silibinin” are two names for one compound. (“Silybinin” is an occasional variant spelling.)
• Silybin A and silybin B are the two naturally co-occurring diastereomers (they differ in configuration at two carbons of the 1,4-dioxane ring); commercial silybin is their ~1:1 mixture, and the B diastereomer tends to be the more potent in several assays ^{3Reference 3Gazák R et al. · 2007Silybin and silymarin—new and emerging applications in medicineView study →}.

Its biosynthetic parent is the flavonoid taxifolin (dihydroquercetin), which couples oxidatively with coniferyl alcohol to build the flavonolignan skeleton ^{2Reference 2Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}. throughout, claims are flagged as belonging to silybin/silibinin the isolate or to the silymarin complex, because the two are routinely — and wrongly — treated as interchangeable.

What It's Used For

Silybin’s research reach is unusually broad for a plant molecule. The evidence is strongest and most human where it matters least commercially (the intravenous antidote) and thinnest where marketing is loudest (everyday oral “liver support”), with the complex standing in for the isolate almost everywhere oral.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Where human data exist they mostly test the silymarin complex, not purified silybin, so scores are capped accordingly.

01Chronic Liver Disease & HepatoprotectionPromising55%Multiple RCTs/meta-analyses of silymarin in NAFLD/NASH ^{12,13,14Reference 12Wah Kheong C et al. · 2017RCTA randomized trial of silymarin for the treatment of nonalcoholic steatohepatitisView study →Reference 13Navarro VJ et al. · 2019RCTSilymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trialView study →Reference 14Zhong S et al. · 2017Meta-analysisThe therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trialsView study →}

02Amatoxin (Amanita) Poisoning AntidotePromising50%Established IV clinical use + defined transporter mechanism ^{8,9Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →Reference 9Letschert K et al. · 2006Molecular characterization and inhibition of amanitin uptake into human hepatocytesView study →}

03Metabolic & Glycaemic ControlShaky42%Meta-analysis of silymarin RCTs in type 2 diabetes ^{15Reference 15Voroneanu L et al. · 2016Meta-analysisSilymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsView study →}

04Liver Fibrosis (Antifibrotic)Shaky40%Human hepatic-stellate-cell + Kupffer-cell mechanism ^{4,5Reference 4Trappoliere M et al. · 2009Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cellsView study →Reference 5Dehmlow C et al. · 1996Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibininView study →}

05Antiviral (Hepatitis C)Shaky38%IV silibinin case series + NS5B inhibition ^{6,7Reference 6Ahmed-Belkacem A et al. · 2010Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymeraseView study →Reference 7Ferenci P et al. · 2008Clinical trialSilibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapyView study →}

06Anticancer (Prostate)Shaky34%Phase I silybin-phytosome + preclinical mechanism ^{10,11Reference 10Ting H et al. · 2013Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancerView study →Reference 11Flaig TW et al. · 2007A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patientsView study →}

07Antioxidant & CytoprotectionShaky30%Class-level radical scavenging / Nrf2 signalling ^{2,3Reference 2Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →Reference 3Gazák R et al. · 2007Silybin and silymarin—new and emerging applications in medicineView study →}

Mechanisms

Pharmacokinetics

Silybin’s defining PK feature is poor oral bioavailability. Free silybin is poorly water-soluble and poorly absorbed, and what is absorbed undergoes rapid and extensive phase II conjugation (glucuronidation and sulfation) in the gut wall and liver, with enterohepatic recirculation; plasma half-life of the parent is short (on the order of a few hours) and most circulating drug is conjugated ^{1,16Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}. Because of this, oral doses of ordinary silymarin deliver low and variable systemic silybin — a key reason in-vitro potencies overstate real-world effect ^{1Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →}.

Two strategies address it. Silybin-phosphatidylcholine complex (Siliphos / “phytosome”) markedly increases silybin absorption and plasma exposure versus unformulated silymarin, and is the form used to reach the higher plasma levels needed for oncology dosing ^{11,16Reference 11Flaig TW et al. · 2007A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patientsView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}; newer phospholipid nanosuspensions push absorption further in preclinical work ^{1Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →}. For the antidote, the problem is bypassed entirely by giving intravenous silibinin dihydrogen disuccinate (Legalon SIL), achieving the hepatic concentrations oral dosing cannot ^{8Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →}.

Silybin also inhibits several drug-metabolising enzymes and transporters — notably CYP2C9 at clinically achievable concentrations, plus other CYPs and P-glycoprotein — the basis of its herb–drug-interaction caveat ^{17Reference 17Brantley SJ et al. · 2010Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrationsView study →}.

Clinical Trials

Oral human trials overwhelmingly test the silymarin complex (NAFLD/NASH, type 2 diabetes); the isolate’s own clinical data are the phase I silybin-phytosome oncology work and the intravenous antidote/antiviral experience.

Last checked: July 2026.

The Oral Bioavailability Problem

More than any single mechanism, bioavailability is the story of silybin. The molecule that a poison-control unit drips into a vein to save a life is the same molecule that a capsule of milk-thistle powder barely delivers to the bloodstream. Unformulated silybin is poorly soluble, poorly absorbed, and swiftly glucuronidated/sulfated, so the plasma exposure achieved from a typical oral supplement is a small fraction of the dose and highly variable between people ^{1,16Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}.

This single fact reconciles the otherwise-confusing literature: robust in-vitro and intravenous effects, but modest and inconsistent oral human outcomes. It is why the credible delivery forms are phospholipid complexes (Siliphos) for oral use and the intravenous route for the antidote — and why whole-seed powder or milk-thistle tea (silymarin is not meaningfully water-soluble) should not be assumed to deliver trial-level effects ^{1,16Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}.

Isolate vs. Plant Studies

The split here is unusually clean and worth stating. The isolated molecule carries the intravenous antidote use (purified silibinin) ^{8Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →}, the direct NS5B enzyme inhibition ^{6Reference 6Ahmed-Belkacem A et al. · 2010Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymeraseView study →}, the hepatic-stellate/Kupffer-cell mechanism ^{4,5Reference 4Trappoliere M et al. · 2009Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cellsView study →Reference 5Dehmlow C et al. · 1996Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibininView study →}, the prostate-cancer preclinical and phase I work (silybin-phytosome) ^{10,11Reference 10Ting H et al. · 2013Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancerView study →Reference 11Flaig TW et al. · 2007A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patientsView study →}, and the CYP2C9 interaction data ^{17Reference 17Brantley SJ et al. · 2010Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrationsView study →}. In contrast, the oral efficacy claims that reach patients — NAFLD/NASH, glycaemic control — almost all test the silymarin complex, not purified silybin ^{12,13,14,15Reference 12Wah Kheong C et al. · 2017RCTA randomized trial of silymarin for the treatment of nonalcoholic steatohepatitisView study →Reference 13Navarro VJ et al. · 2019RCTSilymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trialView study →Reference 14Zhong S et al. · 2017Meta-analysisThe therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trialsView study →Reference 15Voroneanu L et al. · 2016Meta-analysisSilymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsView study →}.

That matters two ways. It is a genuine strength that the flagship human use (the antidote) uses the pure isolate. But it is a caveat that everyday “silybin liver support” borrows its evidence from the complex, delivered in poorly-absorbed oral form — so complex-level trial results should not be quoted as isolated-silybin efficacy, and neither should intravenous results be read across to capsules.

Prevalence in Nature

Silybin is, for practical purposes, a milk-thistle molecule. It occurs in the seeds (achenes) of Silybum marianum as the major flavonolignan of the silymarin complex, which is itself ~1.5–3% of the dried seed; silybin is ~40–60% of that complex, i.e. very roughly 0.6–1.8% of seed by weight, though the figure and the silybin:silychristin:silydianin ratio shift substantially with chemotype, provenance and extraction method ^{1,2Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 2Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}. It is seed-specific — not present in milk-thistle leaves or roots in meaningful amounts — and poorly water-soluble, so it does not partition into aqueous infusions ^{1Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →}.

Trace occurrence has been reported in a few related Silybum/Asteraceae taxa, but milk thistle seed is the only source of any commercial or clinical relevance; no meaningful non-plant source exists ^{2Reference 2Selc M · 2025Looking beyond silybin: the importance of other silymarin flavonolignansView study →}.

Discovery & Synthesis

Silybin was first obtained when Wagner and colleagues in Munich isolated the silymarin complex from milk thistle seed in 1968 and resolved silybin as its principal flavonolignan; the flavonolignan structural class (a flavonoid coupled to a phenylpropanoid lignan unit) was characterised over the following years ^{3Reference 3Gazák R et al. · 2007Silybin and silymarin—new and emerging applications in medicineView study →}. That silybin is in fact a pair of diastereomers, silybin A and silybin B, and their absolute stereochemistry, were established later, and enzymatic and chromatographic methods were subsequently developed to resolve the two ^{3,19Reference 3Gazák R et al. · 2007Silybin and silymarin—new and emerging applications in medicineView study →Reference 19Monti D et al. · 2010Enzymatic kinetic resolution of silybin diastereoisomersView study →}. The name derives from Silybum, the plant genus.

There is no commercial total synthesis — the flavonolignan skeleton is stereochemically awkward, and silybin is obtained by extraction of milk thistle seed followed by purification of the silymarin complex; where single diastereomers or the semi-synthetic silibinin dihydrogen disuccinate (the water-soluble IV salt) are needed, they are prepared from extracted silybin, not built from scratch ^{8,19Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →Reference 19Monti D et al. · 2010Enzymatic kinetic resolution of silybin diastereoisomersView study →}. Its most important “formulation chemistry” is complexation with phosphatidylcholine to make the absorbable Siliphos/phytosome form ^{16Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Silybin has a low toxicity profile: milk-thistle silymarin is well tolerated across trials, adverse effects are usually mild and gastrointestinal (loose stools, nausea) or, rarely, allergic, and even intravenous silibinin at antidote doses (~20 mg/kg/day) has an acceptable safety record in acutely ill patients ^{1,8Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →}. The low grading reflects that combination of long human use, benign trial adverse-event profiles, and a tolerable IV experience — no signal of organ toxicity, mutagenicity or a dangerous therapeutic index at studied doses.

The real caution is pharmacokinetic, not toxicological: silybin inhibits drug-metabolising enzymes and transporters — notably CYP2C9 at clinically achievable concentrations, along with other CYPs and P-glycoprotein — so it can in principle raise levels of co-administered substrates (e.g. warfarin and other CYP2C9-cleared drugs), which is the interaction to watch rather than intrinsic harm ^{17Reference 17Brantley SJ et al. · 2010Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrationsView study →}. Reproductive/developmental toxicity of the isolated molecule has not been specifically characterised; a per-herb or per-supplement pregnancy decision belongs on the milk-thistle monograph, not here. As an Asteraceae product, allergy is possible in sensitive individuals.

Safety at a Glance

✅ Low / no toxicityAllergy risk

• Low intrinsic toxicity. Silymarin/silybin is well tolerated in trials; adverse effects are usually mild and gastrointestinal.
• IV silibinin is used safely in the sickest patients — the Amanita antidote at ~20 mg/kg/day has an acceptable record ^{8Reference 8Mengs U et al. · 2012Clinical trialLegalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoningView study →}.
• Enzyme/transporter inhibition. Silybin inhibits CYP2C9 (and other CYPs) and P-glycoprotein at achievable levels — watch co-medications like warfarin ^{17Reference 17Brantley SJ et al. · 2010Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrationsView study →}.
• Oral bioavailability is poor. Ordinary oral silymarin delivers low, variable silybin; don’t assume capsule/tea = trial effect ^{1,16Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}.
• Asteraceae allergy. Possible in sensitive individuals; a source-herb caution.

Dosage

There is no single established dose for isolated silybin, and the figures below are what research has used, not a recommendation. Oral trials dose the silymarin complex; the antidote is dosed as intravenous silibinin.

Because free silybin is poorly absorbed, salt form and formulation change the effective dose substantially — phospholipid complexes and the IV salt are not interchangeable with plain silymarin powder ^{1,16Reference 1Loguercio C · 2011Silybin and the liver: from basic research to clinical practiceView study →Reference 16Kidd P · 2005ReviewA review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos)View study →}. These are doses studied in research and are not a personal recommendation.

References

1. Loguercio C, Festi D (2011). Silybin and the liver: from basic research to clinical practice. World Journal of Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/21633595/
2. Selc M, Babelova A (2025). Looking beyond silybin: the importance of other silymarin flavonolignans. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/40761399/
3. Gazák R, Walterová D, Křen V (2007). Silybin and silymarin—new and emerging applications in medicine. Current Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/17305535/
4. Trappoliere M, Caligiuri A, Schmid M, et al. (2009). Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. Journal of Hepatology. https://pubmed.ncbi.nlm.nih.gov/19398228/
5. Dehmlow C, Erhard J, de Groot H (1996). Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. https://pubmed.ncbi.nlm.nih.gov/8666328/
6. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. (2010). Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/19962982/
7. Ferenci P, Scherzer TM, Kerschner H, et al. (2008). Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/18771667/
8. Mengs U, Pohl RT, Mitchell T (2012). Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Current Pharmaceutical Biotechnology. https://pubmed.ncbi.nlm.nih.gov/22352731/
9. Letschert K, Faulstich H, Keller D, Keppler D (2006). Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicological Sciences. https://pubmed.ncbi.nlm.nih.gov/16495352/
10. Ting H, Deep G, Agarwal R (2013). Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. The AAPS Journal. https://pubmed.ncbi.nlm.nih.gov/23588585/
11. Flaig TW, Gustafson DL, Su LJ, et al. (2007). A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs. https://pubmed.ncbi.nlm.nih.gov/17077998/
12. Wah Kheong C, Nik Mustapha NR, Mahadeva S (2017). A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. https://pubmed.ncbi.nlm.nih.gov/28419855/
13. Navarro VJ, Belle SH, D’Amato M, et al. (2019). Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial. PLoS One. https://pubmed.ncbi.nlm.nih.gov/31536511/
14. Zhong S, Fan Y, Yan Q, et al. (2017). The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore). https://pubmed.ncbi.nlm.nih.gov/29245314/
15. Voroneanu L, Nistor I, Dumea R, et al. (2016). Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes Research. https://pubmed.ncbi.nlm.nih.gov/27340676/
16. Kidd P, Head K (2005). A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Alternative Medicine Review. https://pubmed.ncbi.nlm.nih.gov/16164374/
17. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF (2010). Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. Journal of Pharmacology and Experimental Therapeutics. https://pubmed.ncbi.nlm.nih.gov/19934397/
18. Vostálová J, Tinková E, Biedermann D, et al. (2019). Skin protective activity of silymarin and its flavonolignans. Molecules. https://pubmed.ncbi.nlm.nih.gov/30875758/
19. Monti D, Gazák R, Marhol P, et al. (2010). Enzymatic kinetic resolution of silybin diastereoisomers. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/20297826/

View all 19 references▾